Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 1997

View Archived Issues

EntreMed: Q3 1997 highlights

Olpadronate associated with improvement in osteogenesis imperfecta

Myriad Genetics and Bayer join forces to develop dementia and depression therapies

Cantab: Q3 1997 highlights

Microcide: Q3 1997 highlights

Clinical trial demonstrates efficacy of NPS-R-568 in hyperparathyroidism

Affymetrix: Q3 1997 highlights

Pharmacia & Upjohn: Q3 1997 highlights

GH secretagogues under development at Merck & Co.

Mitsui Norin discovers natural antiviral/antitumor agent

New triazole antifungals from Pfizer

Lilly claims antithrombotic diamides

Takeda reports novel carbapenems

Brain GABA receptor ligands prepared at Neurogen

DCK analogues with potent and selective anti-HIV activity

Role of complement in mast cell-dependent natural immunity

Favorable results obtained in pediatric study of Neuprex

Phase I trial of multiple-dose IDEC-C2B8 in NHL

New NK1 antagonist from Novartis

Six-month trial of lamivudine for chronic hepatitis B

Role of substance P in PTH secretion described

FDA advisory committee recommends approval of Rocephin for AOM

Doxil/Caelyx evaluated in phase II for advanced breast cancer

NK3 antagonist demonstrates intestinal antiinflammatory activity

Palatin receives FDA clearance to start LeuTech clinical trials

Antifungal activity of KP-103 under evaluation

Gel formulation of diclofenac and hyaluronan effective in aphthous ulcer pain

Novartis launches once-monthly formulation of Sandostatin

Combivir recommended for approval in Europe

Development of new quinolone from Toyama advances

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...